97 related articles for article (PubMed ID: 14670126)
21. Influence of a V kappa 8 L chain transgene on endogenous rearrangements and the immune response to the HA(Sb) determinant on influenza virus.
Carmack CE; Camper SA; Mackle JJ; Gerhard WU; Weigert MG
J Immunol; 1991 Sep; 147(6):2024-33. PubMed ID: 1909739
[TBL] [Abstract][Full Text] [Related]
22. Enhancer-deleted retroviral vectors restore high levels of superoxide generation in a mouse model of CGD.
Schwickerath O; Brouns G; Thrasher A; Kinnon C; Roes J; Casimir C
J Gene Med; 2004 Jun; 6(6):603-15. PubMed ID: 15170731
[TBL] [Abstract][Full Text] [Related]
23. Development of improved adenosine deaminase retroviral vectors.
Onodera M; Nelson DM; Yachie A; Jagadeesh GJ; Bunnell BA; Morgan RA; Blaese RM
J Virol; 1998 Mar; 72(3):1769-74. PubMed ID: 9499026
[TBL] [Abstract][Full Text] [Related]
24. Retroviral hybrid LTR vector strategy: functional analysis of LTR elements and generation of endothelial cell specificity.
Richardson TB; Kaspers J; Porter CD
Gene Ther; 2004 May; 11(9):775-83. PubMed ID: 14999228
[TBL] [Abstract][Full Text] [Related]
25. Comparison of five retrovirus vectors containing the human IL-2 receptor gamma chain gene for their ability to restore T and B lymphocytes in the X-linked severe combined immunodeficiency mouse model.
Avilés Mendoza GJ; Seidel NE; Otsu M; Anderson SM; Simon-Stoos K; Herrera A; Hoogstraten-Miller S; Malech HL; Candotti F; Puck JM; Bodine DM
Mol Ther; 2001 Apr; 3(4):565-73. PubMed ID: 11319919
[TBL] [Abstract][Full Text] [Related]
26. Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations.
Magnusson T; Haase R; Schleef M; Wagner E; Ogris M
J Gene Med; 2011 Jul; 13(7-8):382-91. PubMed ID: 21721074
[TBL] [Abstract][Full Text] [Related]
27. A retroviral vector suitable for ultrasound image-guided gene delivery to mouse brain.
Jang J; Yoon K; Hwang DW; Lee DS; Kim S
Gene Ther; 2012 Apr; 19(4):396-403. PubMed ID: 21900964
[TBL] [Abstract][Full Text] [Related]
28. Effect of posttranscriptional regulatory elements on transgene expression and virus production in the context of retrovirus vectors.
Hlavaty J; Schittmayer M; Stracke A; Jandl G; Knapp E; Felber BK; Salmons B; Günzburg WH; Renner M
Virology; 2005 Oct; 341(1):1-11. PubMed ID: 16054668
[TBL] [Abstract][Full Text] [Related]
29. Increased functional expression of transgene in primary human lymphocytes using retroviral vectors modified with IRES and splicing motifs.
Royal RE; Kershaw MH; Reeves ME; Wang G; Daly T; Treisman J; Lam J; Hwu P
Gene Ther; 2002 Aug; 9(16):1085-92. PubMed ID: 12140736
[TBL] [Abstract][Full Text] [Related]
30. Enhancer sequences located 3' of the mouse immunoglobulin lambda locus specify high-level expression of an immunoglobulin lambda gene in B cells of transgenic mice.
Eccles S; Sarner N; Vidal M; Cox A; Grosveld F
New Biol; 1990 Sep; 2(9):801-11. PubMed ID: 2126202
[TBL] [Abstract][Full Text] [Related]
31. Construction of retroviral vectors with enhanced efficiency of transgene expression.
Hahm SH; Yi Y; Lee DK; Noh MJ; Yun L; Hwang S; Lee KH
J Virol Methods; 2004 Nov; 121(2):127-36. PubMed ID: 15381349
[TBL] [Abstract][Full Text] [Related]
32. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.
Plavec I; Agarwal M; Ho KE; Pineda M; Auten J; Baker J; Matsuzaki H; Escaich S; Bonyhadi M; Böhnlein E
Gene Ther; 1997 Feb; 4(2):128-39. PubMed ID: 9081703
[TBL] [Abstract][Full Text] [Related]
33. T cell-specific expression from Mo-MLV retroviral vectors containing a CD4 mini-promoter/enhancer.
Zhao-Emonet JC; Marodon G; Pioche-Durieu C; Cosset FL; Klatzmann D
J Gene Med; 2000; 2(6):416-25. PubMed ID: 11199262
[TBL] [Abstract][Full Text] [Related]
34. Effects of viral strain, transgene position, and target cell type on replication kinetics, genomic stability, and transgene expression of replication-competent murine leukemia virus-based vectors.
Paar M; Schwab S; Rosenfellner D; Salmons B; Günzburg WH; Renner M; Portsmouth D
J Virol; 2007 Jul; 81(13):6973-83. PubMed ID: 17442710
[TBL] [Abstract][Full Text] [Related]
35. Durable and stratum-specific gene expression in epidermis.
Ghazizadeh S; Doumeng C; Taichman LB
Gene Ther; 2002 Oct; 9(19):1278-85. PubMed ID: 12224010
[TBL] [Abstract][Full Text] [Related]
36. Increased in vitro and in vivo transgene expression levels mediated through cis-acting elements.
Johansen J; Tornøe J; Møller A; Johansen TE
J Gene Med; 2003 Dec; 5(12):1080-9. PubMed ID: 14661183
[TBL] [Abstract][Full Text] [Related]
37. Primary T lymphocytes as targets for gene therapy.
Hanazono Y; Brown KE; Dunbar CE
J Hematother Stem Cell Res; 2000 Oct; 9(5):611-20. PubMed ID: 11091484
[TBL] [Abstract][Full Text] [Related]
38. Hybrid retroviral vector with MCK enhancers inserted in LTR for stable and specific expression of human factor IX in skeletal muscle.
Wang JM; Hou J; Qiu XF; Kurachi K; Xue JL
Chin Med J (Engl); 2004 Jun; 117(6):893-8. PubMed ID: 15198894
[TBL] [Abstract][Full Text] [Related]
39. Expression pattern of CD2 locus control region containing retroviral vectors in hemopoietic cells in vitro and in vivo.
Kaptein LC; Breuer M; Valerio D; van Beusechem VW
Gene Ther; 1998 Mar; 5(3):320-30. PubMed ID: 9614551
[TBL] [Abstract][Full Text] [Related]
40. Cells strongly expressing Ig(kappa) transgenes show clonal recruitment of hypermutation: a role for both MAR and the enhancers.
Goyenechea B; Klix N; Yélamos J; Williams GT; Riddell A; Neuberger MS; Milstein C
EMBO J; 1997 Jul; 16(13):3987-94. PubMed ID: 9233808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
